ClinicalTrials.gg
RecruitingNCT06420440Updated Nov 12, 2026

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

A Phase 2 interventional study of Hepatic arterial infusion chemotherapy and Lenvatinib in HCC, sponsored by Chen Xiaoping. Recruiting at 9 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Chen Xiaoping · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.

Planned enrollment
16th of 121
160 · median 48
Started
2024
with 14 others
Phase 2
66 of 121
33 open now
Primary completion
2026-12
later than 40 of 64 live
Registered
96th of 121
by date

Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 16th largest by planned enrollment, is one of 15 that started in 2024, is one of 66 in phase 2, reaches primary completion later than 40 of the 64 other live ones, and was the 96th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing lenvatinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.

Read the detailed description

The protocol was revised in April 2025 (V1.1). Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect. Although the tumor is in BCLC-A stage, when the tumor diameter is more than 5cm, the effect of surgery is worse than that of single small HCC due to the large resection range, the high risk of surgery and residual disease. In addition, BCLC-stage B and C tumors have a high recurrence rate due to multiple lesions or macrovascular invasion. To address this issue, new tools are urgently needed to guide the selection of appropriate treatment regimens to reduce the risk of postoperative recurrence and improve overall survival.

The investigators multidisciplinary team used deep learning technology to construct an artificial intelligence prediction model of neoadjuvant therapy (Neoadj-Net) benefit based on pre-treatment genetic testing data, digital pathology slides and imaging data (enhanced MRI) of 536 intermediate-stage HCC patients treated with HAIC in combination with lenvatinib and PD-1 monoclonal antibody in six centers, and external center data validated the model's good ability to identify the beneficiary population of the combination regimen ( AUC 0.89, Accuracy 0.86). This study is to explore the effectiveness and safety of Neoadj-Net in reducing postoperative recurrence by observing the benefit of the combined neoadjuvant regimen in patients who are potentially benefited from neoadjuvant therapy and direct surgery from the perspective of precision therapy.

03

Conditions studied

  • HCC

Keywords

  • Hepatocellular carcinoma
  • Neoadjuvant tehrapy
  • recurrence
  • Deep learning
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-75.
  2. No previous local or systemic treatment for hepatocellular carcinoma.
  3. liver function score ≤ 7.
  4. PS 0-1.
  5. No serious organic diseases of the heart, lungs, brain, kidneys, etc.
  6. Enhanced MRI determines that the tumor is technically resectable but at high risk for recurrence(BCLC-A tumor diameter more than or equal to 5cm; BCLC-B; BCLC-C) ; without distant .
  7. Pathologic type of hepatocellular carcinoma confirmed by puncture .
  8. Multimodal Deep Learning Model Screening Based on Pathology, Imaging, and Genetic Data Suggests Benefit from HAIC in Combination with Lenvatinib and inhibitors.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant and lactating women.
  2. Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).
  3. A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication/esophageal varices), as determined by the investigator.
  4. Active infection.
  5. Other significant clinical and laboratory abnormalities that affect the safety evaluation.
  6. Inability to follow the study protocol for treatment or follow up as scheduled.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant therapy group

    Patients in the neoadjuvant group received neoadjuvant therapy prior to surgery (two cycles of HAIC combined with Tislelizumab and Lenvatinib), and adjuvant therapy (Tislelizumab for 8 cycles) after surgery.

    Procedure: Hepatic arterial infusion chemotherapy · Drug: Lenvatinib · Drug: Tislelizumab · Procedure: Liver resection

  • Active comparator
    Direct liver resection group

    Patients in the control group underwent liver resection directly and received adjuvant therapy (Tislelizumab for 8 cycles) after surgery.

    Procedure: Liver resection · Drug: Tislelizumab

Interventions

  • ProcedureHepatic arterial infusion chemotherapy

    Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)

  • Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).

  • Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)

  • ProcedureLiver resection

    Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.

  • Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.

06

What researchers measure

Primary outcomes

  1. Median event-free survival (EFS)

    EFS is defined as the time from randomization to disease recurrence and/or disease progression or death from any cause.

    Time frame: From date of randomization until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 60 months.

Secondary outcomes

  1. Safety Assessment

    Any adverse event during treatment that is incompatible with the therapeutic purpose of the medication.The incidence and severity of adverse events and serious adverse events as assessed by CTCAE v5.0.

    Time frame: Baseline up to 12 months

  2. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause

    Time frame: From date of randomization until the date of death from any cause, assessed up to 60 months.

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 30 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion May 2026 → Dec 2026 and completion May 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 20, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Dec 31, 2026was May 2026
CompletionEst.
Dec 31, 2027was May 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 2 sites removed
Show 9 added (9 China)
  • The First Affiliated Hospital of Guangxi Medical University · Nanning, China
  • Henan Provincial People's Hospital · Zhengzhou, China
  • Jingmen Central Hospital · Jingmen, China
  • Shiyan Taihe Hospital · Shiyan, China
  • Xiangyang Central Hospital · Xiangyang, China
  • Qilu Hospital of Shandong University · Jinan, China
  • The Affiliated Hospital of Qingdao University · Qingdao, China
  • Shandong Provincial Hospital Affiliated to Shandong First Medical University · Jinan, China
  • Shanxi Bethune Hospital · Shanxi, China
Show 2 removed
  • Huapeng Sun · Xiangyang, China
  • Enyu Liu · Jinan, China
Nov 12, 2026
Primary completion
May 31, 2026→Dec 31, 2026
Nov 12, 2026
Study completion
May 31, 2027→Dec 31, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    9 sites added, 2 sites removed
    Show 9 added (9 China)
    • The First Affiliated Hospital of Guangxi Medical University · Nanning, China
    • Henan Provincial People's Hospital · Zhengzhou, China
    • Jingmen Central Hospital · Jingmen, China
    • Shiyan Taihe Hospital · Shiyan, China
    • Xiangyang Central Hospital · Xiangyang, China
    • Qilu Hospital of Shandong University · Jinan, China
    • The Affiliated Hospital of Qingdao University · Qingdao, China
    • Shandong Provincial Hospital Affiliated to Shandong First Medical University · Jinan, China
    • Shanxi Bethune Hospital · Shanxi, China
    Show 2 removed
    • Huapeng Sun · Xiangyang, China
    • Enyu Liu · Jinan, China
    Primary completion May 31, 2026→Dec 31, 2026
    Study completion May 31, 2027→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06420440
Lead sponsor
Chen Xiaoping
Responsible party
Chen Xiaoping (Professor, Tongji Hospital) — Sponsor-investigator
First posted
May 20, 2024
Start date
Jun 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

WanGuang Zhang
Contact
wgzhang@tjh.tjmu.edu.cn
13886195965
xiaoping Chen
Contact
chenxpchenxp@163.com
027-83663400

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion